Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

19 October 2016

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES FIRST NON-EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the Thailand Food and Drug Administration (FDA) for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This approval, the first following the European approval in June, will allow ECO to start selling Aivlosin® in Thailand for the medication of drinking water for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.

Aivlosin^®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Chairman of ECO, commented “This approval from the Thai FDA is an important step in the development of Aivlosin® for commercial layers with Thailand being ranked as a global top twenty egg producing country. ECO has begun the process of submitting the Aivlosin® regulatory files for the treatment of layers in numerous other key egg producing markets. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”

Contacts:

ECO Animal Health Group plc	Â	Â	Â	Peter Lawrence	Â	020 8336 6190
				Marc Loomes		020 8447 8899
						Â
Spiro Financial				Anthony Spiro		020 8336 6196
						Â
Peel Hunt LLP				Dan Webster		020 7418 8900
(Nominated Adviser)				Adrian Trimmings
				George Sellar
						Â

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005833/en/